Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
alleviated, amplified, Asian, carcinosarcoma, checkpoint, concept, conference, cutoff, cycle, daily, diarrhea, differentiated, endometrial, facilitate, filer, FTD, fulfill, gynecological, host, immune, Japan, Korea, lung, lunresertib, Macau, Margaret, moderate, Module, multicenter, nausea, oAnnounced, oEarly, oIn, oInitiated, oPreliminary, oPublished, oRoche, Oxley, paclitaxel, potency, proof, rash, RECIST, recurrent, regimen, rest, reverted, South, Southeast, Taiwan, TAPISTRY, territory, unmet, vomiting, waived, weekly
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view